How should urinary incontinence be evaluated and managed in a 60-year-old woman?

Management of Urinary Incontinence in a 60-Year-Old Woman

Begin with pelvic floor muscle training (PFMT) for stress incontinence, bladder training for urgency incontinence, or both combined for mixed incontinence—these nonpharmacologic approaches are first-line therapy and should be attempted before any medications. 1

Initial Evaluation: Determine the Type of Incontinence

Before initiating treatment, you must identify which type of incontinence is present:

• Stress UI: Leakage with coughing, sneezing, laughing, or physical exertion (urethral sphincter failure)
• Urgency UI: Leakage preceded by sudden, compelling urge to void
• Mixed UI: Combination of both stress and urgency symptoms

Key history questions to ask:

• Timing of leakage (with physical activity vs. sudden urge)
• Frequency and severity of episodes
• Impact on quality of life and daily activities
• Presence of obesity (important modifiable risk factor)
• Medications that may worsen incontinence (anticholinergics, diuretics)
• Screen for reversible causes: urinary tract infection, constipation, cognitive impairment, urinary retention 1

Essential physical examination components:

• Perform cough stress test to demonstrate stress incontinence
• Assess for pelvic organ prolapse
• Measure post-void residual urine volume to rule out overflow incontinence
• Check for fecal impaction 2

Treatment Algorithm Based on Incontinence Type

For Stress Incontinence

Step 1: Pelvic Floor Muscle Training (PFMT)

• This is the only recommended first-line treatment for stress UI 1
• High-quality evidence shows PFMT increases continence rates and improves quality of life
• Can be enhanced with biofeedback using vaginal EMG for proper technique
• Do NOT use systemic pharmacologic therapy for stress UI—strong recommendation against this approach 1

Step 2: If obese, add weight loss and exercise

• Strong recommendation for obese women with any type of UI 1
• Moderate-quality evidence supports significant improvement

Step 3: Consider vaginal estrogen (if applicable)

• Vaginal estrogen formulations improved stress UI in postmenopausal women
• Avoid transdermal estrogen patches—these worsened UI 1

For Urgency Incontinence

Step 1: Bladder training

• First-line treatment with strong recommendation and moderate-quality evidence 1
• Behavioral therapy involving scheduled voiding with progressively extended intervals
• Adding PFMT to bladder training does NOT improve outcomes for pure urgency UI 1

Step 2: Pharmacologic therapy if bladder training fails

• Only proceed to medications after unsuccessful bladder training 1
• All antimuscarinic agents are equally effective, so choose based on tolerability and adverse effects 1

Medication selection based on adverse effect profile:

• Best tolerated (lowest discontinuation rates):

  • Tolterodine: Discontinuation rate similar to placebo 1
  • Darifenacin: Discontinuation rate similar to placebo 1
  • Solifenacin: Lowest risk for discontinuation among active drugs 1

• Avoid as first choice:

  • Oxybutynin: Highest discontinuation rate (NNTH = 16) due to adverse effects including dry mouth, constipation, blurred vision 1
  • Fesoterodine: Higher discontinuation than tolterodine (NNTH = 33) 1

Common adverse effects to counsel patients about:

• Dry mouth, constipation, blurred vision (antimuscarinics)
• Nasopharyngitis, GI disorders (mirabegron, a β3-adrenoceptor agonist) 1

For Mixed Incontinence

Combine PFMT with bladder training

• Strong recommendation with moderate-quality evidence 1
• This combination improves continence and UI symptoms in mixed incontinence
• Address obesity if present with weight loss and exercise 1

Critical Pitfalls to Avoid

1. Do not prescribe systemic pharmacologic therapy for stress incontinence—it doesn't work and wastes resources 1

2. Do not skip nonpharmacologic therapy and jump to medications—PFMT and bladder training are effective, cheaper, and have minimal adverse effects compared to drugs 1

3. Do not use transdermal estrogen for stress UI—it worsens incontinence 1

4. Do not start with oxybutynin if prescribing for urgency UI—it has the highest discontinuation rate due to adverse effects 1

5. Screen for reversible causes before labeling as chronic UI: UTI, medications (anticholinergics, morphinics), urinary retention, fecal impaction, cognitive impairment 1, 3

6. Measure post-void residual to rule out overflow incontinence, which requires completely different management 2

When to Refer

Consider urology/urogynecology referral if:

• Hematuria present
• Recurrent urinary tract infections
• Pelvic pain or history of pelvic radiation
• Recent pelvic surgery
• Failed conservative and pharmacologic management
• Unclear diagnosis after initial evaluation 3, 2

Special Considerations for This 60-Year-Old Patient

At age 60, this patient is in the peak prevalence age group (45-59 years: 30-50% prevalence) 1. Women in this age group often have multiple contributing factors including menopause, prior childbirth trauma, and possibly obesity. The treatment approach remains the same regardless of age—start with nonpharmacologic interventions, which are effective even in elderly women and avoid the medication burden that can be problematic in older adults 4, 5.

If the patient is obese, weight loss combined with exercise is a strong recommendation with moderate-quality evidence showing significant benefit 1. This addresses a modifiable risk factor and improves outcomes across all incontinence types.